EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial

Martin Bøg, Anders Bo Bojesen, Scott Emerson, Milana Ivkovic, Nia C Jenkins, Christopher Lübker, Muhammad Mamdani, Thomas Padgett, Luc Van Gaal, Peter E Weeke, A Michael Lincoff

PharmacoEconomics · 2026

DOI: 10.1007/s40273-025-01580-2 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PharmacoEconomics, 2026. Verfasst von Martin Bøg und 10 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk A/S, Vandtårnsvej 108, 2860, Søborg, Denmark. AXBQ@novonordisk.com. Hauptthemen laut MEDLINE: Overweight, Obesity, Acute Coronary Syndrome, Stroke. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Overweight and obesity is a prevalent and growing global health concern associated with a significant healthcare burden. With recent advancements in weight management interventions demonstrating cardioprotective benefits, there is a need for risk equations that can accurately predict cardiovascular event risk in health economic models to support healthcare decision making and resource allocation. OBJECTIVE: We aimed to derive risk equations using SELECT trial data that estimate the risk of acute coronary syndrome and stroke in people with established cardiovascular disease and overweight or obesity but without diabetes mellitus for use in health economic modelling. METHODS: Risk equations estimating first in-trial observed acute coronary syndrome and stroke were derived from patient-level data from the SELECT trial, a double-blind randomised placebo-controlled trial comparing semaglutide 2.4 mg with placebo. Risk factors were identified from the literature and by clinical experts. Risk equations were developed using cause-specific Cox proportional hazard models with all-cause mortality as a competing risk. Least absolute shrinkage and selection operator (LASSO) penalisation was applied 100 times in bootstrap samples to refine the risk equations. Final risk equations were validated with clinical experts and using SELECT trial data. RESULTS: Sex, coronary heart disease, a history of acute coronary syndrome and use of angina medications had the strongest associations with acute coronary syndrome (hazard ratio 1.67-1.82). For stroke, a history of atrial fibrillation, cerebrovascular disorder, stroke and transient ischaemic attack had the strongest associations (hazard ratio 1.40-1.70). In terms of discrimination, the risk equations had an area under the receiver operating characteristic curve (AUC) of 0.66-0.68 for acute coronary syndrome and 0.68-0.71 for stroke, and C-indices of 0.67-0.69 for acute coronary syndrome and 0.66-0.69 for stroke. The risk equations showed good cohort-level predictive capabilities over a 4-year time horizon. CONCLUSIONS: These novel, treatment-specific, trial-derived risk equations are the first to predict the risk of secondary cardiovascular events in people with overweight or obesity and established cardiovascular disease but without diabetes. Incorporating these risk equations into health economic models may improve the accuracy of economic evaluations in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OverweightObesityAcute Coronary SyndromeStrokeCardiovascular DiseasesModels, EconomicHumansFemaleMaleDouble-Blind MethodRisk AssessmentMiddle AgedProportional Hazards ModelsSemaglutideRisk FactorsAged

Substanzen

Semaglutide

Autor:innen und Institutionen

  • Novo Nordisk A/S, Vandtårnsvej 108, 2860, Søborg, Denmark. AXBQ@novonordisk.com.
  • Novo Nordisk A/S, Vandtårnsvej 108, 2860, Søborg, Denmark.
  • University of Washington, Seattle, WA, USA.
  • Health Economics and Outcomes Research Ltd., Cardiff, UK.
  • Unity Health Toronto, Toronto, ON, Canada.
  • University Hospital Antwerp, Antwerp, Belgium.

Zitieren

APA

Bøg, M., Bojesen, A. B., Emerson, S., Ivkovic, M., Jenkins, N. C., Lübker, C., Mamdani, M., Padgett, T., Van Gaal, L., Weeke, P. E., & Lincoff, A. M. (2026). Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial. PharmacoEconomics. https://doi.org/10.1007/s40273-025-01580-2

Vancouver

Bøg M, Bojesen AB, Emerson S, Ivkovic M, Jenkins NC, Lübker C, et al. Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial. PharmacoEconomics. 2026. doi:10.1007/s40273-025-01580-2

BibTeX
@article{Bg2026,
  author = {Bøg, Martin and Bojesen, Anders Bo and Emerson, Scott and Ivkovic, Milana and Jenkins, Nia C and Lübker, Christopher and Mamdani, Muhammad and Padgett, Thomas and Van Gaal, Luc and Weeke, Peter E and Lincoff, A Michael},
  title = {Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial},
  journal = {PharmacoEconomics},
  year = {2026},
  doi = {10.1007/s40273-025-01580-2}
}
Kostenlos starten →